Granted Patent B2

US 12,703,753 · App. 17/439,972 · Granted Aug 11, 2026

Inventors: Hangjun Zhan (Foster City, CA); Lam Nguyen (Union City, CA); Richard Chin (San Francisco, CA); Fawn Qian (Burlingame, CA); Shyr Jiann Li (Millbrae, CA); Qingyi Chu (Burlingame, CA)

Assignee: Elanco US Inc.

C07K16/2875C12N9/12A61K38/00C07K2319/30C07K2319/31C12Y207/10001

Abstract

Claims (18)

1 . A polypeptide comprising at least one extracellular domain of a TrkA polypeptide (TrkA ECD polypeptide) from a companion animal species and a fusion partner;

wherein the TrkA ECD polypeptide comprises SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5, except that the TrkA ECD polypeptide comprises a pair of cysteine substitutions selected from the group consisting of:

a) a cysteine at a position corresponding to position 7 and position 89 of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4; or

b) a cysteine at a position corresponding to position 5 and position 87 of SEQ ID NO: 5; or

c) a cysteine at position 7 and position 89 of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4; or

d) a cysteine at position 5 and position 87 of SEQ ID NO: 5.

2 . The polypeptide of claim 1 , wherein the polypeptide binds to an NGF polypeptide with a dissociation constant (Kd) of less than 5×10 −6 M, less than 1×10 −6 M, less than 5×10 −7 M, less than 1×10 −7 M, less than 5×10 −8 M, less than 1×10 −8 M, less than 5×10 −9 M, less than 1×10 −9 M, less than 5×10 −10 M, less than 1×10 −10 M, less than 5×10 −11 M, less than 1×10 −11 M, less than 5×10 −12 M, or less than 1×10 −12 M, as measured by biolayer interferometry.

3 . The polypeptide of claim 2 , wherein the NGF polypeptide is a human NGF polypeptide, a canine NGF polypeptide, a feline NGF polypeptide, or an equine polypeptide.

4 . The polypeptide of claim 1 , wherein the polypeptide reduces NGF signaling in the companion animal species, wherein the companion animal species is canine, feline, or equine.

5 . The polypeptide of claim 1 , wherein the polypeptide comprises a linker.

6 . The polypeptide of claim 1 , wherein the fusion partner is an Fc polypeptide.

7 . The polypeptide of claim 1 , wherein the fusion partner is a Fc polypeptide comprising a wild-type or a variant canine IgG-A, IgG-B, IgG-C, or IgG-D polypeptide.

8 . The polypeptide of claim 1 comprising the formula:

TrkA ECD 1-L1-Fc;

wherein TrkA ECD 1 is a TrkA ECD polypeptide, L1 is a linker, and Fc is a wild type or variant IgG Fc polypeptide of a companion animal species.

9 . The polypeptide of claim 1 further comprising at least one extracellular domain of an NGFR polypeptide (NGFR ECD polypeptide).

10 . A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

11 . A method of treating a companion animal species having an NGF-induced condition or pain, the method comprising administering to the companion animal species a therapeutically effective amount of the polypeptide of claim 1 .

Assignments (2)

Continuity (2)

References Cited (77)